Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 3/20 | 0.59 |
| ▸ | TP53 | P04637 | 3/20 | 0.59 |
| ▸ | MDM2 | Q00987 | 6/20 | 0.55 |
| ▸ | CASP3 | P42574 | 2/20 | 0.54 |
| ▸ | TLR2 | O60603 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31427164 | 1.00 | MDM4 (0.59) | MDM4TP53MDM2CASP3TLR2 | |
| SCHEMBL29432858 | 1.00 | MDM4 (0.59) | MDM4TP53MDM2CASP3TLR2 | |
| SCHEMBL15681926 | 1.00 | MDM4 (0.59) | MDM4TP53MDM2CASP3TLR2 | |
| SCHEMBL30802555 | 1.00 | MDM4 (0.59) | MDM4TP53MDM2CASP3TLR2 | |
| SCHEMBL16463752 | 0.93 | MDM2 (0.58) | MDM4TP53MDM2CASP3TLR2 | |
| SCHEMBL20530570 | 0.93 | MDM2 (0.58) | MDM4TP53MDM2CASP3TLR2 | |
| SCHEMBL25362302 | 0.91 | MDM2 (0.57) | MDM4TP53MDM2CASP3TLR2 | |
| SCHEMBL30854537 | 0.91 | MDM2 (0.57) | MDM4TP53MDM2CASP3TLR2 | |
| SCHEMBL4600023 | 0.91 | MDM2 (0.57) | MDM4TP53MDM2CASP3TLR2 | |
| SCHEMBL30278748 | 0.91 | MDM2 (0.57) | MDM4TP53MDM2CASP3TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4540267-B1 | CYCLIC PEPTIDES FOR TRAPPING INTERLEUKIN-1 BETA | MERCK SHARP & DOHME LLC (US) | 2026-04-15 | — | — | EP | disclosed |
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-07-29 | — | — | US | disclosed |
| WO-2024258943-A1 | METHODS OF USING CYCLIC PEPTIDES FOR TRAPPING INTERLEUKIN-1 BETA | MERCK SHARP & DOHME LLC (US) | 2024-12-19 | — | — | WO | disclosed |
| US-20240400617-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-12-05 | — | — | US | disclosed |
| WO-2024098039-A2 | POTENT ASGPR-BINDING HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-05-10 | — | — | WO | disclosed |
| US-20240148821-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-09 | — | — | US | disclosed |
| EP-4316503-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-02-07 | — | — | EP | disclosed |
| CN-117279655-A | Pharmaceutical use of cyclic peptide compounds | 中外制药株式会社 | 2023-12-22 | — | — | CN | disclosed |
| US-20230406885-A1 | CYCLIC PEPTIDES FOR TRAPPING INTERLEUKIN-1 BETA | MERCK SHARP & DOHME LLC (US) | 2023-12-21 | — | — | US | disclosed |
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2023-08-17 | — | — | US | disclosed |
| US-6828427-B1 | Oligomeric aminodiol-containing compounds, libraries thereof, and process of preparing the same | ISIS PHARMACEUTICALS, INC. | 2004-12-07 | — | — | US | disclosed |
| EP-0751948-B1 | NOVEL PHOSPHORAMIDATE AND PHOPHOROTHIOAMIDATE OLIGOMERIC COMPOUNDS | ISIS PHARMACEUTICALS INC (US) | 2002-09-25 | — | — | EP | disclosed |
| US-6184389-B1 | FEATURE A PLURALITY OF FUNCTIONAL GROUPS ATTACHED TO BACKBONE AND PHOSPHORAMIDATE SITES | ISIS PHARMACEUTICALS, INC. | 2001-02-06 | — | — | US | disclosed |
| EP-0865439-A4 | COMBINATORIAL LIBRARIES HAVING AMINODIOL MONOMER SUBUNITS | ISIS PHARMACEUTICALS INC (US) | 1998-11-11 | — | — | EP | disclosed |
| EP-0865439-A1 | COMBINATORIAL LIBRARIES HAVING AMINODIOL MONOMER SUBUNITS | ISIS PHARMACEUTICALS, INC. (US) | 1998-09-23 | — | — | EP | disclosed |
| US-5717083-A | COMPLEXING WITH PROTEINS, NUCLEIC ACIDS, LIPIDS | ISIS PHARMACEUTICALS, INC. (US) | 1998-02-10 | — | — | US | disclosed |
| EP-0751948-A4 | NOVEL PHOSPHORAMIDATE AND PHOPHOROTHIOAMIDATE OLIGOMERIC COMPOUNDS | ISIS PHARMACEUTICALS INC (US) | 1997-03-19 | — | — | EP | disclosed |
| EP-0751948-A1 | NOVEL PHOSPHORAMIDATE AND PHOPHOROTHIOAMIDATE OLIGOMERIC COMPOUNDS | ISIS PHARMACEUTICALS, INC. (US) | 1997-01-08 | — | — | EP | disclosed |
| WO-1996040672-A1 | COMBINATORIAL LIBRARIES HAVING AMINODIOL MONOMER SUBUNITS | ISIS PHARMACEUTICALS, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| WO-1995023160-A1 | NOVEL PHOSPHORAMIDATE AND PHOPHOROTHIOAMIDATE OLIGOMERIC COMPOUNDS | ISIS PHARMACEUTICALS, INC. (US) | 1995-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230406885-A1 | CYCLIC PEPTIDES FOR TRAPPING INTERLEUKIN-1 BETA | IL1A, IL1B, IL1R1 | MDM4 4837/4885TP53 3017/4885MDM2 4355/4885 |
| US-20240400617-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | MDM4 441/4885TP53 34/4885MDM2 164/4885 |
| US-20240148821-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | VIP, IAPP, KRAS | MDM4 1294/4885TP53 178/4885MDM2 1604/4885 |
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | DNPEP, BCAT1, ANPEP | MDM4 1648/4885TP53 614/4885MDM2 423/4885 |
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | KRAS, NRAS, HRAS | MDM4 441/4885TP53 34/4885MDM2 164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.